Perspective Therapeutics, Inc. (NYSEAM: CATX)
Health Care · Biotechnology · US
$2.46
+4.24% today · -29.1% 1Y
Perspective Therapeutics, Inc. (NYSEAM: CATX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $280.81M and employs 165 people.
Over the last twelve months the share price has lost 29.1%, trading between 1.96 and 6.16.
Tweenvest scores Perspective Therapeutics, Inc. across four factors: quality 36/100, value 32/100, growth 0/100. Its strongest factor is quality.
CATX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $280.81M
- Revenue (TTM)
- $409.00K
- P/E
- —
- EPS
- -1.25
- Dividend yield
- —
- Beta (5Y)
- 1.85
- 52-week high
- $6.16
- 52-week low
- $1.96
- Avg volume (3M)
- —
- Shares outstanding
- 114.15M
- Employees
- 165
- Next earnings
- —
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
- ISIN
- US46489V3024
- Founded
- 2004
- Listed since
- Nov 10, 2005
- Exchange
- NYSE American LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Abeona Therapeutics Inc.NasdaqCM: ABEO | $287.64M | $5.08 | +0.99% |
| CytoDyn Inc.OTCPK: CYDY | $287.21M | $0.20 | -11.89% |
| Eurobio Scientific Société anonymeENXTPA: ALERS | $284.43M | €25.10 | 0.00% |
| Rocket Pharmaceuticals, Inc.NasdaqGM: RCKT | $281.02M | $2.54 | -0.98% |
| X4 Pharmaceuticals, Inc.NasdaqCM: XFOR | $280.59M | $2.81 | -0.71% |
| Vanda Pharmaceuticals Inc.NasdaqGM: VNDA | $279.94M | $4.56 | -1.51% |
| Inventage Lab, Inc.KOSDAQ: A389470 | $279.64M | ₩28,300.00 | +15.51% |
| Santhera Pharmaceuticals Holding AGSWX: SANN | $279.31M | CHF14.68 | -2.91% |
Figures last refreshed Oct 4, 2026.